Celldex Therapeutics reported $-21396000 in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Agenus AGEN:US $ -44972000 8.98M
Amgen AMGN:US $ 2176M 324M
Applied Genetic Technologies AGTC:US $ -13481000 4.8M
Aptinyx Inc APTX:US $ -17105000 2.27M
Biocept BIOC:US $ -2707000 68.54K
Bristol Myers Squibb BMY:US $ 3197M 9M
Celldex Therapeutics CLDX:US $ -21396000 1.86M
Cytrx CYTR:US -1294610 692.11K
Glaxosmithkline GSK:US 1.82B 600M
Immunogen IMGN:US $ -61053000 38.2M
Merrimack Pharmaceuticals MACK:US $ -486000 91K
Nektar Therapeutics NKTR:US $ -47713000 67.37M
Newlink Genetics NLNK:US -7924000 193K
Northwest Biotherapeutics NWBO:US -21099000 8.81M
Pfizer PFE:US $ 12099M 2104M
Seattle Genetics SGEN:US $ -133111000 61K